Molnupiravir: the treatment for COVID-19 (waiting for approval) that sabotages your RNA

Okie dokie, so Merck, which was the original manufacturer and previously a large dispenser of Ivermectin, has developed a new antiviral drug, Molnupiravir, and they're hoping the FDA will grant emergency authorization for its use as the first oral treatment for COVID-19. Much like Ivermectin, it's aimed for use as a prophylactic or in the early stages of the disease.

The company is reportedly set to receive approximately $1.2 billion to supply around 1.7 million courses of Molnupiravir to the United States government, giving it a cost per 5-day course of around $700 (40 times what it costs to make!), versus between $0.60 and $ 1.80 for Ivermectin. (More info in this article.)

So, should we consider this drug a 'better' treatment than Ivermectin - or any of the other repurposed drugs out there that seem to be having great results? Are they claiming it's more effective? Probably. But what do people unrelated to Big Pharma think?

Well, on the 99th Dark Horse podcast, Brett Weinstein says that (as he understands it) Molnupiravir targets RNA inside the body and causes it to malfunction. That's ALL RNAs in your body, not just viral RNAs.

That doesn't sound like a great idea to me - much as getting cells all over your body to produce pathogenic spike proteins that circulate in your bloodstream doesn't sound too good a plan. Brett ends simply by saying: "The apparent mechanism of action of this drug raises questions."

From Dark Horse Podcast #99 - Excerpt 1:01:12 – 1:06:24

Right, so what exactly is Molnupiravir - what does it do?

Molnupiravir is an ‘active metabolite’, converted in the liver into NHC-5 Triphosphate, which acts as a ‘competitive alternative substrate for viral RNA’. Dr John Campbell (see video below) says that his understanding is: “It gets into the new RNA molecule and sabotages it” – so the cell can’t produce the thing it was trying to.

This is a helpful little video, where John Campbell goes through a paper published 10th August 2021 that compares the basic and clinical pharmacology of Molnupiravir and Ivermectin.

(First 20 mins only)

From the paper: “There is some concern about the safety of NHC-nucleoside triphosphate, which is also mutagenic to mammalian cells.” John expands: “So the idea here is that if it stops the normal replication of RNA, is it going to stop the normal replication of our own DNA?” - and that’s what Brett Weinstein is also concerned about. (Although Merck says it’s not a problem. Of course.)

And big red flags are being waved by Dr Jane Ruby. Appearing on the Stew Peters Show, she says: “This is, by its own mechanism of action, a cancer-causing medication.”

“People need to stop thinking that this is a super-Ivermectin. It is nothing of the sort.”

- Dr Jane Ruby

While we await the virtually inevitable approval from the FDA, you can track real-time Molnupiravir study outcomes online here.